Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

Journal of Clinical Oncology

Volumn 23, Issue 11, 2005, Pages 2469-2476

  Gutierrez, M Carolina ^a   Detre, Simone ^a   Johnston, Stephen ^a   Mohsin, Syed K ^a   Shou, Jiang ^a   Allred, D Craig ^a   Schiff, Rachel ^a   Osborne, C Kent ^a   Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR RESISTANCE; XENOGRAFT; ADJUVANT CHEMOTHERAPY; ANIMAL; BIOPSY; BREAST TUMOR; DISEASE COURSE; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOUSE; NUDE MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 17844398046     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.172     Document Type: Article

References (49)

1. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
2. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
3. Ingle JN: Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 10:362S-367S, 2004
4. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793-1802, 2003
5. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
6. Schiff R, Massarweh S, Shou J, et al: Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9:447S-454S, 2003 (suppl)
7. Nicholson RI, McClelland RA, Robertson JF, et al: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6:373-387, 1999
8. Font de Mora J, Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20:5041-5047, 2000
9. Lee AV, Cui X, Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7:4429s-4435s, 2001 (suppl 12)
10. Schiff R, Massarweh SA, Shou J, et al: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S-336S, 2004 (suppl)
11. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst 96:926-935, 2004
12. Anzick SL, Kononen J, Walker RL, et al: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968, 1997
13. List HJ, Reiter R, Singh B, et al: Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 68:21-28, 2001
14. Murphy LC, Simon SL, Parkes A, et al: Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 60:6266-6271, 2000
15. Knowlden JM, Hutcheson IR, Jones HE, et al: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044, 2003
16. Campbell RA, Bhat-Nakshatri P, Patel NM, et al: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 276:9817-9824, 2001
17. Ciocca DR, Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13:1-10, 2000
18. Mass R: The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 27:46-52, 2000
19. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003
20. Perez-Tenorio G, Stal O: Activation of AKT/ PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545, 2002
21. Gee JM, Robertson JF, Ellis IO, et al: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247-254, 2001
22. Ellis MJ, Jaenicke F, Llombart CA, et al: A randomized double-blind multicenter study of pre-operative tamoxifen versus Femara (letrozole) for postmenopausal women with ER and/ or PgR positive breast cancer ineligible for breast-conserving surgery. Correlation of clinical response with tumor gene expression and proliferation, in Lippman ME (ed): San Antonio Breast Cancer Symposium. San Antonio, TX, Kluwer Academic Publishers, 2000, pp 29
23. Smith IE, Dowsett M: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 82:S6, 2003 (abstr 1)
24. Zhu L, Chow LW, Loo WT, et al: Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib anti-aromatase neoadjuvant trial. Clin Cancer Res 10:4639-4644, 2004
25. Schiff R, Reddy P, Ahotupa M, et al: Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 92:1926-1934, 2000
26. Johnston SR, Lu B, Scott GK, et al: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5:251-256, 1999
27. Shou J, Weigel NL, Osborne CK, et al: Onset of endocrine resistance in breast cancer is associated with increased active p38MAPK. Breast Cancer Res Treat 69:254, 2001 (abstr 272)
28. Jiang Y, Chen C, Li Z, et al: Characterization of the structure and function of a new mitogen-activated protein kinase (p38). J Biol Chem 271:17920-17926, 1996
29. Bode AM, Dong Z: Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003:RE2, 2003
30. Lee H, Jiang F, Wang Q, et al: MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol 14:1882-1896, 2000
31. Lee H, Bai W: Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 22:5835-5845, 2002
32. Johnston SR, Boeddinghaus IM, Riddler S, et al: Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res 59:3646-3651, 1999
33. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
34. Osborne CK, Coronado E, Allred DC, et al: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477-1482, 1991
35. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750, 1995
36. Gross GE, Clark GM, Chamness GC, et al: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44:836-840, 1984
37. Encarnacion CA, Ciocca DR, McGuire WL, et al: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-246, 1993
38. Kuukasjarvi T, Kononen J, Helin H, et al: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14:2584-2589, 1996
39. Johnston SR, Saccani-Jotti G, Smith IE, et al: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331-3338, 1995
40. Osipo C, Gajdos C, Liu H, et al: Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95:1597-1608, 2003
41. Cui X, Zhang P, Deng W, et al: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575-588, 2003
42. Petz LN, Ziegler YS, Schultz JR, et al: Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 18: 521-532, 2004
43. Meng S, Tripathy D, Shete S, et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393-9398, 2004
44. Hutcheson IR, Knowlden JM, Madden TA, et al: Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81:81-93, 2003
45. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
46. Wu RC, Qin J, Yi P, et al: Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 15:937-949, 2004
47. Esteva FJ, Sahin AA, Smith TL, et al: Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100:499-506, 2004
48. Yao J, Xiong S, Klos K, et al: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20:8066-8074, 2001
49. Vadlamudi R, Adam L, Talukder A, et al: Serine phosphorylation of paxillin by heregulin-beta1: Role of p38 mitogen activated protein kinase. Oncogene 18:7253-7264, 1999